BACKGROUND: Persons who use drugs (PWUD) face substantial risk of Staphylococcus aureus infections. Limited data exist describing clinical and substance use characteristics of PWUD with invasive S. aureus infections or comparing treatment and mortality outcomes in PWUD vs non-PWUD. These are needed to inform optimal care for this marginalized population. METHODS: We identified adults hospitalized from 2013 to 2018 at 2 medical centers in San Francisco with S. aureus bacteremia or International Classification of Diseases-coded diagnoses of endocarditis, epidural abscess, or vertebral osteomyelitis with compatible culture. In addition to demographic and clinical characteristic comparison, we constructed multivariate Cox proportional hazards models for 1-year infection-related readmission and mortality, adjusted for age, race/ethnicity, housing, comorbidities, and methicillin-resistant S. aureus (MRSA). RESULTS: Of 963 hospitalizations for S. aureus infections in 946 patients, 372 of 963 (39%) occurred in PWUD. Among PWUD, heroin (198/372 [53%]) and methamphetamine use (185/372 [50%]) were common. Among 214 individuals using opioids, 98 of 214 (46%) did not receive methadone or buprenorphine. PWUD had lower antibiotic completion than non-PWUD (70% vs 87%; P < .001). While drug use was not associated with increased mortality, 1-year readmission for ongoing or recurrent infection was double in PWUD vs non-PWUD (28% vs 14%; adjusted hazard ratio [aHR], 2.0 [95% confidence interval {CI}: 1.3-2.9]). MRSA was independently associated with 1-year readmission for infection (aHR, 1.5 [95% CI: 1.1-2.2]). CONCLUSIONS: Compared to non-PWUD, PWUD with invasive S. aureus infections had lower rates of antibiotic completion and twice the risk of infection persistence/recurrence at 1 year. Among PWUD, both opioid and stimulant use were common. Models for combined treatment of substance use disorders and infections, particularly MRSA, are needed.
BACKGROUND: Persons who use drugs (PWUD) face substantial risk of Staphylococcus aureus infections. Limited data exist describing clinical and substance use characteristics of PWUD with invasive S. aureus infections or comparing treatment and mortality outcomes in PWUD vs non-PWUD. These are needed to inform optimal care for this marginalized population. METHODS: We identified adults hospitalized from 2013 to 2018 at 2 medical centers in San Francisco with S. aureus bacteremia or International Classification of Diseases-coded diagnoses of endocarditis, epidural abscess, or vertebral osteomyelitis with compatible culture. In addition to demographic and clinical characteristic comparison, we constructed multivariate Cox proportional hazards models for 1-year infection-related readmission and mortality, adjusted for age, race/ethnicity, housing, comorbidities, and methicillin-resistant S. aureus (MRSA). RESULTS: Of 963 hospitalizations for S. aureus infections in 946 patients, 372 of 963 (39%) occurred in PWUD. Among PWUD, heroin (198/372 [53%]) and methamphetamine use (185/372 [50%]) were common. Among 214 individuals using opioids, 98 of 214 (46%) did not receive methadone or buprenorphine. PWUD had lower antibiotic completion than non-PWUD (70% vs 87%; P < .001). While drug use was not associated with increased mortality, 1-year readmission for ongoing or recurrent infection was double in PWUD vs non-PWUD (28% vs 14%; adjusted hazard ratio [aHR], 2.0 [95% confidence interval {CI}: 1.3-2.9]). MRSA was independently associated with 1-year readmission for infection (aHR, 1.5 [95% CI: 1.1-2.2]). CONCLUSIONS: Compared to non-PWUD, PWUD with invasive S. aureus infections had lower rates of antibiotic completion and twice the risk of infection persistence/recurrence at 1 year. Among PWUD, both opioid and stimulant use were common. Models for combined treatment of substance use disorders and infections, particularly MRSA, are needed.
Authors: Natasha E Holmes; John D Turnidge; Wendy J Munckhof; James O Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Wei Gao; Keryn J Christiansen; Geoffrey W Coombs; Paul D R Johnson; Benjamin P Howden Journal: J Infect Dis Date: 2011-08-01 Impact factor: 5.226
Authors: Håkan Hanberger; Sten Walther; Marc Leone; Philip S Barie; Jordi Rello; Jeffrey Lipman; John C Marshall; Antonio Anzueto; Yasser Sakr; Peter Pickkers; Peter Felleiter; Milo Engoren; Jean-Louis Vincent Journal: Int J Antimicrob Agents Date: 2011-07-28 Impact factor: 5.283
Authors: Raghava Potula; Brian J Hawkins; Jonathan M Cenna; Shongshan Fan; Holly Dykstra; Servio H Ramirez; Brenda Morsey; Michael R Brodie; Yuri Persidsky Journal: J Immunol Date: 2010-07-28 Impact factor: 5.422
Authors: Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli Journal: Clin Infect Dis Date: 2002-12-13 Impact factor: 9.079
Authors: John A Rossow; Radhika Gharpure; Julia Brennan; Pryanka Relan; Sabrina R Williams; Snigdha Vallabhaneni; Brendan R Jackson; Caroline R Graber; Sherry R Hillis; William Schaffner; John R Dunn; Timothy F Jones Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Mircea Radu Mihu; Jessica Roman-Sosa; Avanish K Varshney; Eliseo A Eugenin; Bhavikkumar P Shah; Hiu Ham Lee; Long N Nguyen; Allan J Guimaraes; Bettina C Fries; Joshua D Nosanchuk; Luis R Martinez Journal: mBio Date: 2015-10-27 Impact factor: 7.867
Authors: Laura R Marks; Juan J Calix; John A Wildenthal; Meghan A Wallace; Sanjam S Sawhney; Eric M Ransom; Michael J Durkin; Jeffrey P Henderson; Carey-Ann D Burnham; Gautam Dantas Journal: Commun Med (Lond) Date: 2021-11-30
Authors: Stephanie S Gelman; Eddie Stenehjem; Rachel A Foster; Nick Tinker; Nancy Grisel; Brandon J Webb Journal: Open Forum Infect Dis Date: 2021-12-10 Impact factor: 3.835